Langlois Nicole J, Wells Philip S
Clinical Epidemiology Unity, Ottawa Health Research Institute, Ontario, Canada.
Thromb Haemost. 2003 Jul;90(1):17-26.
Clinical equipoise exists regarding whether relatives of individuals with venous thromboembolism (VTE) and thrombophilia should be screened for thrombophilia. There have been no systematic attempts to summarize studies that have assessed the incidence of VTE in relatives. The purpose of this review was to systematically identify and review observational studies with thrombophilic relatives and to summarize their findings with respect to their risk of VTE. We conducted a systematic literature review and included nine observational studies meeting a priori inclusion criteria. Potentially eligible studies evaluated VTE incidence in relatives of index patients (probands) with symptomatic thrombophilia. In the four prospective studies, the incidence of VTE for asymptomatic family members with factor V Leiden ranged from 0.58-0.67% per year, 1.0-2.5% for protein C deficiency, 0.7-2.2% for protein S deficiency, and 4% for antithrombin deficiency. About half of all VTEs occurred during well-known risk periods but incidence rates were decreased by use of prophylaxis. No deaths from pulmonary embolism or fatal hemorrhages from anticoagulants were reported. The incidence of VTE was generally lower in the retrospective studies. The pooled relative risk from four retrospective studies for factor V Leiden carriers was 3.69 (CI 2.27, 6.00) and from two studies the pooled relative risk for deficiencies of protein C, protein S, and antithrombin was 10.58 (CI 5.38, 20.81). In conclusion, the risk of VTE events in asymptomatic relatives is low, but this may be an underestimate. Anticoagulant prophylaxis during risk periods appears to be of benefit but further research in this area is required.
对于静脉血栓栓塞症(VTE)患者及血栓形成倾向者的亲属是否应进行血栓形成倾向筛查,临床上存在着两种观点。此前尚无系统的尝试对评估亲属中VTE发病率的研究进行总结。本综述的目的是系统地识别和回顾有关血栓形成倾向亲属的观察性研究,并总结他们在VTE风险方面的研究结果。我们进行了一项系统的文献综述,纳入了九项符合先验纳入标准的观察性研究。潜在符合条件的研究评估了有症状血栓形成倾向的索引患者(先证者)亲属中的VTE发病率。在四项前瞻性研究中,携带因子V莱顿突变的无症状家庭成员每年的VTE发病率为0.58 - 0.67%,蛋白C缺乏者为1.0 - 2.5%,蛋白S缺乏者为0.7 - 2.2%,抗凝血酶缺乏者为4%。所有VTE事件中约有一半发生在已知的风险期,但通过预防措施发病率有所降低。未报告有因肺栓塞死亡或因抗凝剂导致致命出血的情况。回顾性研究中VTE的发病率通常较低。四项回顾性研究中因子V莱顿突变携带者的合并相对风险为3.69(95%置信区间2.27, 6.00),两项研究中蛋白C、蛋白S和抗凝血酶缺乏者的合并相对风险为10.58(95%置信区间5.38, 20.81)。总之,无症状亲属发生VTE事件的风险较低,但这可能被低估了。在风险期进行抗凝预防似乎有益,但该领域还需要进一步研究。